Quick Summary
- Novartis has completed its purchase of Avidity Biosciences at $72.00 per share, valuing the company at approximately $12 billion. Avidity now operates as a wholly owned Novartis subsidiary.
- The deal brings Novartis Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform a technology that precisely delivers RNA therapies directly to muscle cells, along with three late-stage neuromuscular disease programs that competitors have struggled to replicate.
- Novartis expects the acquired programs to support its 5–6% net sales CAGR target through 2030, with planned product launches that could unlock significant commercial opportunities for patients with currently untreatable genetic neuromuscular diseases.
Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
Under the terms of the merger, Novartis acquired Avidity through its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc. Former Avidity stockholders received $72.00 per share in cash, and Avidity’s shares have now ceased trading on the Nasdaq Stock Market. Avidity operates as an indirect, wholly owned subsidiary of Novartis going forward.
What is Avidity Biosciences and Why Did Novartis Pay $12 Billion?
Avidity Biosciences is a clinical-stage biopharmaceutical company best known for its proprietary Antibody Oligonucleotide Conjugate (AOC™) platform, a novel technology that combines the tissue-targeting precision of monoclonal antibodies with the gene-silencing power of RNA therapeutics. Unlike conventional RNA-based medicines that struggle to reach muscle tissue efficiently, Avidity’s platform is specifically engineered to deliver oligonucleotides directly to muscle cells, a breakthrough capability that has eluded the field for decades.
This platform underpins three late-stage clinical programs targeting devastating genetic neuromuscular disease conditions with significant unmet medical need and limited existing treatment options. For Novartis, acquiring Avidity represents a direct acceleration of its xRNA strategy, an ambitious effort to develop next-generation RNA-based medicines across disease areas.
Read More: Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio
Strengthening Novartis’ Neuromuscular Pipeline Ahead of 2030 Launches
The strategic rationale is clear: Novartis is already one of the leaders in the neuromuscular disease space, and the addition of Avidity’s programs dramatically reinforces that position. The Swiss drugmaker says the deal is expected to support its 2025–2030 net sales compound annual growth rate (CAGR) target of 5–6% in constant currency, while also strengthening its medium- to long-term growth outlook.
Critically, Novartis has signaled that the acquired programs could enable planned product launches before 2030, potentially unlocking what the company describes as multi-billion-dollar commercial opportunities. Given the rarity and severity of the conditions being targeted, combined with the novelty of the AOC mechanism, these programs could command significant pricing power in markets currently lacking effective disease-modifying treatments.
The Growing Race in RNA Therapeutics and Neuromuscular Disease
The Novartis-Avidity deal arrives at a time of intense competition in both RNA therapeutics and the neuromuscular disease space. Major players including Sarepta Therapeutics, Roche, and Biogen have all been investing heavily in treatments for conditions like Duchenne muscular dystrophy (DMD), myotonic dystrophy, and facioscapulohumeral muscular dystrophy (FSHD) — all areas where AOC-based approaches have shown early promise.
The key differentiator for Avidity’s platform is muscle selectivity. Traditional antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are difficult to deliver specifically to muscle tissue in therapeutically meaningful quantities. By conjugating these oligonucleotides to antibodies that bind receptors expressed on muscle cells, Avidity’s AOC technology achieves the kind of targeted delivery that could make the difference between a therapy that works and one that doesn’t.
With three programs already in late-stage development, Novartis is acquiring de-risked assets a meaningful distinction at a time when early-stage RNA companies often command high valuations with limited clinical proof of concept.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Integration and Milestones to Watch
Now that the deal has closed, market observers and investors will be watching several key milestones:
- Pipeline readouts: Data from Avidity’s late-stage clinical trials will be closely scrutinized for efficacy and safety signals that support regulatory submissions.
- Regulatory filings: Novartis has suggested launches are possible before 2030, meaning NDA or BLA submissions to the FDA (and equivalents globally) could come within the next two to three years.
- Platform expansion: Beyond the three inherited programs, the AOC platform itself could serve as a launchpad for Novartis to develop new muscle-targeted RNA medicines, potentially expanding the pipeline into adjacent neuromuscular indications.
- Commercial infrastructure: Novartis will now need to build or adapt commercial capabilities for rare neuromuscular diseases, a specialty area that requires highly specialized patient identification and access programs.
Last Modified:
